Broken String Biosciences appoints Bruce Eaton to board
Broken String Biosciences has appointed Bruce Eaton as Chairman of the Board.
The appointment from the biotechnology company allows it to drive the global commercialisation of its INDUCE-seq platform, which it says can provide rapid, unbiased, genome-wide measurement of on- and off-target DNA breaks directly in customers’ own labs.
Eaton’s experience spans operations, business development and corporate strategy across the biotech sector. He recently served as Executive Vice President, CTO and CBO for Editas Medicine, where he led the company’s R&D programme in sickle cell anaemia.
“Bruce’s expertise in commercial strategy will be invaluable to us as we look to position INDUCE-seq as the gold-standard solution for gene editing off-target assessment. I am extremely pleased to welcome him to the Broken String team,” said Terry Pizzie, CEO of Broken String Biosciences.
“These are exciting times for the company – following the submission of our FDA Master File for INDUCE-seq, we are now uniquely placed to support gene editing teams through IND with unbiased insights into genome integrity.”
“Gene editing therapeutics have the potential to transform today’s therapeutic landscape, however they are held back by the disparity between regulatory expectation and technological capabilities,” Eaton commented.
“INDUCE-seq directly tackles this challenge, providing comprehensive, cell-based assessment of on- and off-target effects.
“I look forward to working closely with the board and leadership team, to drive an effective commercial strategy and enable gene editing teams worldwide to confidently progress their candidates towards the clinic.”
